Allogene Therapeutics (ALLO) Stock Soars 41% Following Breakthrough CAR-T-Cell Trial Results

Shares of Allogene Therapeutics surged more than 41% on April 13, 2026, after the company disclosed encouraging interim results from its Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) in patients with high-risk large B-cell lymphoma. The update followed an interim futility analysis from the trial.

Interim efficacy: MRD negativity advantage

In the initial cohort of 24 randomized participants, 58.3% of patients treated with cema-cel achieved minimal residual disease (MRD) negativity. In the observation group, 16.7% reached the same benchmark, a difference of 41.6 percentage points.

The study uses Natera’s investigational CLARITY MRD assay to identify high-risk patients prior to clinical relapse becoming apparent. The trial also frames cema-cel as a potential first-line consolidation treatment, which would position the therapy earlier than most existing CAR-T approaches.

Safety profile: no CRS, no ICANS, no treatment-related serious adverse events

The interim readout also reported a notably clean safety profile. No treated participants developed cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), complications commonly associated with CAR-T therapies. The company also reported zero treatment-related serious adverse events.

Baird analysts cited the safety results as a key differentiator when comparing cema-cel with second-line autologous CAR-T alternatives. The potential for outpatient administration, combined with the favorable safety metrics, was also highlighted as a possible competitive advantage, given that many current CAR-T treatments require inpatient care.

Analyst actions and probability of success

After the data announcement, Baird raised its ALLO price objective from $7.00 to $9.00 and kept an Outperform recommendation. The firm also increased its probability of success estimate for the program to 70%.

Baird noted that the limited dataset size of 12 treated patients should be viewed with caution, while still describing the early results as a positive signal for the therapy’s commercial potential in the first-line setting.

Trial scale and upcoming milestones

The ALPHA3 study is recruiting approximately 220 participants across more than 60 clinical sites. Efficacy endpoints remain blinded at this stage, and the available dataset is still limited.

Scheduled interim event-free survival analyses are expected in 2027, with complete primary results projected for 2028. Favorable outcomes from these assessments could support a future biologics license application submission.

Market reaction and other coverage

On April 13, ALLO shares rose to $3.87 from the previous session’s close of $2.91. The stock has gained approximately 99% year-to-date and is trading near its 52-week peak.

Jefferies initiated coverage on ALLO with a Buy recommendation and a $6.00 price objective. Citizens maintained a Market Outperform stance with a $5.00 target price.

InvestingPro analysis indicates the stock is valued above its calculated fair value, while the company’s balance sheet shows cash holdings exceeding debt obligations.